bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-71-3418

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report 30 days (Slide received to report)
 
Useful For (ประโยชน์การทดสอบ):
MI Tumor Seek (test by NGS), plus PD-L1, plus MMR testing.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.

MMR genes create a system for recognizing and repairing mistakes that arise during DNA replication. If the MMR genes themselves become damaged or mutated, they will not work properly and the mistakes made during replication will not be repaired. This leaves the cell vulnerable and unhealthy. Cells without normal MMR genes can develop more and more mistakes with each new copy, resulting in a normal healthy cell losing the ability to stop dividing, or growing, once it has appropriately replaced itself. The ability to stop dividing, or growing, is what causes a colon cell to become cancerous. 
 
Methodology (วิธีการทดสอบ):
Next-generation sequencing (NGS)
 
Test List In Profile (การทดสอบใน Profile):
All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
IHC: PD-L1, MMR
 
AliasesName (ชื่อเรียกอื่นๆ) :
Comprehensive Genomic Profiling, Tissue
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3418

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
NGS: FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
IHC: 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test
 
Sub Mission Container (ภาชนะส่งตรวจ):
Specimen collection kit
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Specimen was insufficient for testing (Low cellularity, Low tumor purity, DNA highly fragmentation, Low of RNA quality)
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3418

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
Method detail (วิธีการทดสอบ):
Next-generation sequencing (NGS)
 
Schedule (ตารางการทดสอบ):
N/A **Sent out to Caris, USA
 
Turnaround Time (ระยะเวลารอผล):
Received specimen to report 30 days (Slide received to report)
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Caris Life Sciences, USA
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code (รหัสการทดสอบ):
090-71-3418

Order Name (ชื่อการทดสอบ):
Caris - MI Tumor seek & PD-L1 & MMR, tissue (FFPE) **

 
 
Reference Value (ค่าอ้างอิง):
An interpretive report will be provided.
 
Clinical Reference (เอกสารอ้างอิง):
www.carislifesciences.com (Retrieved: 25 Jun 2020)